Nicole Lambert
Vermögen: 1 Mio $ am 31.05.2026
Vermögen: 1 Mio $ am 31.05.2026
Nicole Lambert is currently an Independent Director at Arcus Biosciences, Inc. since 2021 and President at Myriad Genetic Laboratories, Inc. Formerly, Ms. Lambert was Chief Operating Officer at Myriad Genetics, Inc. from 2022 to 2023.
Education includes undergraduate studies at Boston College and graduate studies at Icahn School of Medicine at Mount Sinai.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC. 0,03 % | 11.06.2026 | 43.000 ( 0,03 % ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 03.08.2021 |
Myriad Genetic Laboratories, Inc.
Myriad Genetic Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Provides cancer predisposition testing services | Präsident | - |
| Unternehmen | Position | Ende |
|---|---|---|
| MYRIAD GENETICS, INC. | Geschäftsführer | 31.10.2023 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Myriad Genetics, Inc.
Myriad Genetics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic and predictive medicine products | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Myriad Genetic Laboratories, Inc.
Myriad Genetic Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Provides cancer predisposition testing services | Commercial Services |
Arcus Biosciences, Inc.
Arcus Biosciences, Inc. BiotechnologyHealth Technology Develops and commercializes novel therapies for the treatment of lung & gastrointestinal cancers | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen